Allergan to lose license in Canada to sell breast implants

Apr. 04, 2019 2:22 PM ETAllergan plc (AGN)AGNBy: Douglas W. House, SA News Editor8 Comments
  • Subsequent to its assessment of textured breast implants, Health Canada has informed Allergan (AGN +1.9%) that it intends to suspend its marketing license for its Biocell line.
  • The regulator is taking action after being notified of 28 confirmed cases there of breast implant recipients developing anaplastic large cell lymphoma, 24 involving Biocell.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.